Patients who have drug-resistant tuberculosis have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine.
A new study has identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small-cell lung cancer treated with a combination of immunotherapy and low-dose radiation.
Weill Cornell researchers find inflammatory bowel disease drug works by modulating the activity of a group of gut bacteria that are more abundant in patients who respond to the drug.
An experimental mRNA vaccine against human cytomegalovirus, a common virus that can infect babies during pregnancy, elicited some of the most promising immune responses to date of any vaccine candidate, according to a study by Weill Cornell Medicine investigators.
Cornell’s participation in the U.S. Commerce Department initiative will help advance development and deployment of safe and trustworthy artificial intelligence technology.
A multicenter, phase 3 clinical trial has found that apixaban is no more effective than aspirin at preventing a second stroke in patients diagnosed with a milder, related condition called atrial cardiopathy, according to new research.
Alessio Accardi, professor of physiology and biophysics in anesthesiology at Weill Cornell Medicine, has been awarded a five-year, $2.7 million grant for fundamental research on cell membrane proteins that have critical roles in biology and are involved in numerous human diseases.
Jeannine Gerhardt, an assistant professor of stem cell biology in obstetrics and gynecology and in reproductive medicine at Weill Cornell Medicine, has received a five-year, $2.1 million grant for the study of repetitive DNA and RNA sequences and the mechanisms by which they cause cell dysfunction and diseases.
